Patent Strategies By: GBI Research | - The pharmaceutical industry is going to experience major patent expiries during 2010-2014, of which 2010 to 2012 are expected to be peak years, with the loss of patents for drugs whose sales were more than $60 billion during 2009.
In 2010, major drugs like Lipitor, Cozaar, Advair, Arimidex, Flomax and Gemzar, with combined sales revenues of more than $24 billion, are expected to face generic competition. In 2011, nine drugs of six companies are going to experience a major impact of ... Tags:Patent Strategies, Product Lifecycles, Generics Markets
Vision Care (contact Lenses And Spectacle Lenses) By: GlobalData | - The pharmaceutical industry is going to experience major patent expiries during 2010-2014, of which 2010 to 2012 are expected to be peak years, with the loss of patents for drugs whose sales were more than $60 billion during 2009.
In 2010, major drugs like Lipitor, Cozaar, Advair, Arimidex, Flomax and Gemzar, with combined sales revenues of more than $24 billion, are expected to face generic competition. In 2011, nine drugs of six companies are going to experience a major impact of ... Tags:Vision Care, Contact Lenses, Spectacle Lenses, Medical Devices
Drug Markups And The Role Of Supplements By: Pat Boardman | - The gigantic drug industry captitalizes on the consumer's search for security from symptoms. The profit margin is partially due to low-cost ingredients being marked up on a scale that any other industry would envy. Sharon Davis and Mary Palmer, budget analysts for the United States Department of Commerce did an independent study on the costs of the active ingredients in commercial drugs in America relative to the consumer price. They published articles on their findings in several issues of Life ... Tags:leg cramps, rls, legs, insomnia, sleep, treatment, restless leg syndrome, restless legs, remedy
